Plus: Pfizer drug extends survival for some bladder cancer patientsAugust 12, 2025Check out STAT+Sponsored By NIH STAT+ | Peptide vaccine could limit pancreatic cancer progression, small study finds A peptide vaccine showed strong immune responses in most pancreatic cancer patients in an early trial, hinting at a new way to stop recurrence. By Veronica Paulus STAT+ | Pfizer drug extends survival for some bladder cancer patients Padcev, an antibody-drug conjugate that the drug giant acquired through its purchase of Seagen, was combined with Keytruda in clinical trial. By Matthew Herper NIH director: mRNA vaccine contracts were canceled because public lacks trust in technology The explanation offered by Jay Bhattacharya does not not align with that of his boss, health secretary Robert F. Kennedy Jr. By Helen Branswell More around STATIn case you missed it Why lung cancer is a 'hidden epidemic' in this part of the world, NPR (written by STAT alum Simar Bajaj!) Bayer, Kumquat Biosciences team up on potential new cancer drug, WSJ Dear Vinay: Please embrace dissent and fade into the background, STAT Inside the research machine that helps UnitedHealth protect its Medicare profits, STAT Former surgeon general: The CDC shooting must be a wakeup call, STAT Check out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments